The prognosis of superficial bladder cancer in terms of recurrence and disease progression is related to bladder tumor multiplicity and the presence of concomitant "plane" tumors such as high-grade dysplasia and carcinoma in situ. This study in 33 patients aimed to demonstrate the role of fluorescence cystoscopy in transurethral resection of superficial bladder cancer. The method is based on the detection of protoporphyrin-IX-induced fluorescence in urothelial cancer cells by topical administration of 5-aminolevulinic acid. The sensitivity and the specificity of this procedure on apparently normal mucosa in superficial bladder cancer are estimated to be 82.9% and 81.3%, respectively. Thus, fluorescence cytoscopy is a simple and reliable method for mapping the bladder mucosa, especially in the case of multifocal bladder disease, and it facilitates the screening of occult dysplasia.
Introduction
In superficial bladder transitional cell carcinoma, tumor multiplicity and concomitant urothelial atypia are indicators of a poor disease prognosis [1, 2] . High-grade dyspla-sia or carcinoma in situ point to a higher risk of recurrence or progression [I, 3] . Occasionally, reddish and mossy spots of the bladder mucosa allow the localization by biopsy of these foci of dysplasia, but mostly no specific changes of the bladder wall can be recognized by white light cystoscopy [4] .
Although its accuracy is highly variable, urinary bladder cytology as a routine test in the early detection of bladder cancer and in the patient monitoring after treatment is well established, but does not enable concomitant urothelial atypia at the time of the first bladder tumor resection to be discovered. Moreover, the usefulness of random biopsies from normal-looking mucosa has recently been seriously questioned [5] . Therefore, as for epithelial cancers of other organs such as the oesophagus or the uterine cervix, there is a need to localize urothelial atypia during the endoscopic exploration.
Simple methods such as mucosal staining with methylene blue have failed due to lack of sensitivity and specificity [6] . Fluorescence studies correlated with histology on cystectomy specimens after intravenous injection ofhematoporphyrin derivatives have demonstrated the possible role of a photodynamic method for detecting and localizing dysplasia and carcinoma in situ in bladder cancer [7] . However, the sophisticated equipment needed to obtain good images, the lack of selectivity of the photosensitizer and the risk of skin photosensitization have limited its application for clinical routine practice in urology. Recently, the high fluorescence contrast and intensity observed when treating cutaneous in situ tumors by photodynamic therapy using the endogenous photosensitizer protoporphyrin IX (PpIX), induced by the topical application of 5-aminolevulinic acid (ALA), has suggested the same approach to be suitable for detection and treatment of epithelial tumors of other organs, such as the oesophagus and the bladder [8] . The first clinical reports on the photodetection of early transitional cell carcinoma by light-induced fluorescence of PpIX following topical administration of ALA [9, 11] stimulated interest in this new method of mapping the bladder mucosa in search of dysplasia or carcinoma in situ. $4 By comparison to the first system of bladder wall illumination with a krypton ion laser, the new light source, a xenon arc lamp, considerably simplifies the procedure by enabling the investigator to examine the bladder wall in real time without the necessity for an auxiliary device. This study presents our experience with this new system and attempts to assess the accuracy of the method in the detection of high-grade dysplasia and carcinoma in situ.
Material and method
Fifty milliliters of a 3% solution of ALA, buffered with 5 ml phosphate-buffered saline (PBS) and adjusted to a pH of 5.3 with 7 ml sodium hydroxide (1 N), were instilled into the bladder through a 16-French Foley catheter about 6 h before photodetection. Patients were asked to keep the catheter closed for 4 h to optimize the exposure of the bladder wall to the photosensitizing solution. The light source was a filtered xenon arc lamp which produced either white light for conventional cystoscopy or blue light with a wavelength range of 380-450 nm to excite the sensitized bladder mucosa. A foot pedal was used to switch from white to blue light and vice versa when necessary. The power of the fluorescence excitation light at the end of the cystoscope ranged between 150 and 480 mW, giving under normal conditions of use a power density of 2 65 mW/cm . The white light, the blue excitation light and the resulting tissue fluorescence were transmitted through the optical fiber bundle of a Storz cystoscope or resectoscope. Two optics of 0 ° and of 30 °, suitable for either a cystoscope or resectoscope sheath, were specially configured to optimize the light transmission. As the PpIX emission peak was 635 nm, a long-pass filter (X>490 nm) was adapted to the ocular piece of the cystoscope to transmit the red and cut out most of the blue-reflected excitation light. Thus, the fluorescent spots appeared red, whereas the non-fluorescent mucosa stayed green. The somewhat darker bladder wall vessels facilitated the positioning of the cytoscope during the operation.
Starting in January t995, 33 bladder examinations were performed in 31 patients, 23 male patients and 8 female patients (two patients had two successive operations). Mean age was 66.1, ranging from 44 to 84 years. Eleven patients were operated on for the first time, 6 for the second time and 16 for the third time or more. Topical chemotherapy or immunotherapy with bacille Calmette-Gu6rin (BCG) was added to the previous surgical treatment in 19 patients. Bladder urinary cytological examination was regularly performed when the catheter was introduced for the ALA instillation.
The operation always started with a careful bladder inspection under white light in order to note the presence, number and location of all the visible tumors and suspicions areas. To evaluate the sensitivity and the specificity of the method in patients with bladder tumors, a four-quadrant random biopsy of the normal bladder mucosa was performed for each patient as follows: the randomly designated spot of normal mucosa under white light was excited under blue light to determine the fluorescence response and then immediately sampled by forceps for biopsy. A total of 132 random biopsies were obtained in this way, 51 in fluorescent areas and 81 in nonfluorescent areas. All other fluorescent areas on an apparently normal or slightly irregular mucosa under white light were also biopsled and sent for analysis. The transurethral resection of significant tumors was generally performed under fluorescence, except in the case of major bleeding. Papillary and nonpapillary urothelial carcinomas were graded and staged according to the WHO 1973 classified [12] and the IUCC/AJC-1992 system [13] , respectively. Flat intraepithelial neoplastic lesions were graded according to the criteria of Nagy et al. [14] , and classified as grade 1 (mild dysplasia), grade 2 (moderate dysplasia), grade 3 (marked dysplasia) and in situ carcinoma.
Results
No systemic or local side effects following ALA bladder instillation either before or after the photodetection procedure were noted. Except for one pTaG1 tumor, all papillary tumors visible on white light cystoscopy were fluorescent. The correlations between the fluorescence findings and the presence or absence of cancer cells for the 132 random biopsies on apparently normal mucosa are shown in Table 1 . The predictive value of a positive fluorescence corresponding to a tumor is estimated at 66.6% (34/51), and the predictive value of a negative fluorescence corresponding to benign tissue at 91.3 % (74/81). The sensitivity of this photodetection method in superficial bladder cancer can be estimated at 82.9% (34/41) and the specificity at 81.3% (74/91).
In 22/33 patients, 66.6% of our collective, 47 tumors were detected by the fluorescence ( Table 2 ). Seven of these 22 patients (31.8%) had grade 3 dysplasia or carcinoma in situ (CIS). Table 3 shows the correlations between cytology, white light cystoscopy and fluorescence findings for each patient. The fluorescence method detected additional urothelial atypia, invisible under white light, in 12/14 patients (85%) with multiple tumors and in 5/12 patients (41%) with a single tumor. In contrast to the fluorescence cytoscopy, urinary cytology was not really helpful in patients with macroscopic tumors. For patients previously operated on for a superficial bladder cancer, who presented no specific lesion on white light cystoscopy, fluorescence cystoscopy confirmed the absence of neoplastic lesions in three and detected urothelial atypia or even a small tumor in four of them. In these cases, urinary cytology could only give an indication of the presence or absence of cancerous cells, whereas fluorescence cytoscopy precisely delineated the number of carcinomatous spots. 
Discussion
In the Canton of Vaud in Switzerland, the incidence of superficial bladder cancer is around 18.6/100 000 per year in male patients and 4.2/100000 per year in female patients, which represents a ratio of 4:1 [15] . The individual risk of cancer progression, reflecting the natural history of the disease, varies from 4 to 45% [16] . Moreover, in the year following the first treatment, superficial bladder cancer tends to recur in a proportion up to 70%; and 10-20% of recurrences on the site of the initial tumor grow from carcinomatous foci left during the first operation [17] . If the characterization of dysplastic changes in the urothelium is important in the evaluation of the disease prognosis and the risk of recurrence, the surgical treatment of all exophytic and "flat" tumors during the first operation is mandatory. So far no reliable method has been available to determine the cancer cells in delineating the tumor basis and screening urothelial atypia. PpIX-induced fluorescence detection of urothelial cancer cells by topical administration of ALA is a simple and harmless method for this. No local or systemic reaction was noted after ALA bladder instillation or illumination with the xenon blue light. The correlation between the fluorescence tissue response and the histopathological diagnosis on normal mucosa in superficial bladder cancer establishes that a fluorescent spot corresponds to a carcinoma in about two out of three cases and above all that a nonfluorescent spot corresponds to benign tissue in nine out of ten cases. Undoubtedly, fluorescence cystoscopy aids in the biopsy of the urothelium at the right place in bladder cancer. The electrocoagulation of false-positive fluorescent areas, due to inflammatory or hyperplastic cells, does not harm the bladder with normal compliance.
The sensitivity and the specificity of the procedure on apparently normal mucosa in patients with superficial bladder cancer is estimated at 82.9% and 81.3%, respectively. Calculated on a per patient basis it has been estimated at 94.2% by the Munich group [10] . Following the same approach in our collective, bladder biopsies revealed dyspastic urothelial changes or CIS in 23 patients, among whom 22 had a positive fluorescence. Thus, our per patient estimated sensitivity is near 95.6%, an equivalent value to the previous estimation.
Fluorescence cystoscopy constitutes a previous aid to white light cystoscopy. It is a simple and a reliable method in mapping the mucosa in bladder cancer. It facilitates the delineation of tumors and the screening of occult dysplastic changes, especially in multiple papillary bladder disease. In addition, it appears very useful in monitoring the patients after treatment.
Subsequent studies will be needed to assess whether the optimal transurethal bladder resection obtained with fluorescence cytoscopy contributes to a reduction of the risk of recurrence in superficial bladder cancer.
